Expertise in
4
conditions

Paul A. Fields

Uclh
London, ENG, GB 
Expertise in
4
conditions
Uclh
London, ENG, GB 

Overview

Paul Fields practices practicing medicine in London, United Kingdom.

Mr. Fields is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), Adult T-Cell Leukemia, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Kidney Transplant.

He is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

UCLH
London, ENG, United Kingdom
Other Locations
1959 NE Pacific Street, Seattle, WA 98195
Guy's and St Thomas' NHS Trust
London, ENG, United Kingdom
77 Massachusetts Avenue, Cambridge, MA 02139

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC
Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC
Enrollment Status: Completed
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Vincristine, Prednisolone, Fludarabine
Study Phase: Phase 3
A Phase II Study of Nivolumab Monotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Fit for Autologous Stem Cell Transplant Who Fail to Reach Complete Metabolic Remission After First or Second Line Salvage Therapy
A Phase II Study of Nivolumab Monotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Fit for Autologous Stem Cell Transplant Who Fail to Reach Complete Metabolic Remission After First or Second Line Salvage Therapy
Enrollment Status: Unknown
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Drug
Study Drugs: Romidepsin, Carfilzomib
Study Phase: Phase 1/Phase 2
A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: July 13, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

88 Total Publications

Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity.
Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity.
Journal: NPJ vaccines
Published: September 09, 2025

Frequently Asked Questions about Paul A. Fields

Is Paul A. Fields a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Paul A. Fields is classified as an Distinguished expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Paul A. Fields participate in research or clinical trials?

Yes. Paul A. Fields has published 88 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Paul A. Fields's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fields's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile